SCHEMBL5537417

SCHEMBL5537417

CC(=O)Nc1ccc(CCCO[C]=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 1/20 0.47
POLB P06746 1/20 0.47
TSHR P16473 2/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
ALDH1A1 P00352 4/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
HPGD P15428 3/20 0.45
RAB9A P51151 2/20 0.45
KDM4E B2RXH2 1/20 0.45
CYP2C19 P33261 1/20 0.45
RECQL P46063 2/20 0.44
HTT P42858 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
THRA P10827 1/20 0.43
THRB P10828 1/20 0.43
CA12 O43570 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5547876 0.95 THRA (0.46) AOC3POLBTSHRSMN1; SMN2ALDH1A1
SCHEMBL5542152 0.94 THRA (0.48) AOC3POLBTSHRSMN1; SMN2ALDH1A1
SCHEMBL5536165 0.94 THRA (0.48) AOC3POLBTSHRSMN1; SMN2ALDH1A1
SCHEMBL5537937 0.91 AOC3 (0.49) AOC3POLBTSHRSMN1; SMN2ALDH1A1
SCHEMBL5537299 0.83 HDAC3 (0.58) POLBSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL5543539 0.82 CYP17A1 (0.50) SMN1; SMN2ALDH1A1HPGDRAB9ARECQL
SCHEMBL1902060 0.82 SMN1; SMN2 (0.59) AOC3POLBTSHRSMN1; SMN2ALDH1A1
SCHEMBL11116153 0.82 SMN1; SMN2 (0.59) AOC3POLBTSHRSMN1; SMN2ALDH1A1
SCHEMBL11201779 0.80 POLB (0.50) AOC3POLBTSHRSMN1; SMN2ALDH1A1
SCHEMBL5536240 0.79 HDAC3 (0.57) POLBSMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 AOC3 259/4885POLB 1637/4885TSHR 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.